UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of February, 2009
Commission
File Number
________________
Novogen
Limited
(Translation
of registrant’s name into English)
140 Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
o
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
o
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes
o
No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf
by the undersigned, thereunto duly
authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
27 February, 2009
NOVOGEN
LIMITED
ABN
37-063-259-754
www.novogen.com
140 Wicks Road, NORTH RYDE,
NSW
2113
Telephone:
02 9878 0088
APPENDIX
4D
incorporating
INTERIM
FINANCIAL REPORT
FOR
THE HALF-YEAR
31
DECEMBER, 2008
Lodged
with the ASX under Listing Rule 4.2A
This is a
half-yearly report. It is to be read in conjunction with the most recent annual
financial report.
Novogen
Limited
Appendix
4D Specific Requirements
31
December, 2008
RESULTS
FOR ANNOUNCEMENT TO THE MARKET
$‘000
|
|
|
|
$’000
|
|
|
|
|
|
Revenues
from ordinary activities
|
down
|
6.6%
|
to
|
6,375
|
|
|
|
|
|
Loss
from ordinary activities after tax attributable to members
|
down
|
6.8%
|
to
|
(8,960)
|
|
|
|
|
|
Net
Loss for the period attributable to members
|
down
|
6.8%
|
to
|
(8,960)
|
The
Directors do not propose to pay a dividend.
Refer to
Review of Operations shown in the attached Directors’ Report for an explanation
of the above disclosures.
Novogen
Limited
Directors’
Report
31
December, 2008
Directors’
report for the half-year 31 December, 2008
Your
Directors submit their report for the half-year ended 31 December,
2008.
Directors
The names
and qualifications of the Directors that held office during the half-year and up
to the date of this report, unless otherwise indicated, are as
follows:-
Mr PA
Johnston
, Chairma
n and Non-Executive Director – Dip
Eng (Production)
Mr C
Naughton,
Managing Director –
BEc, LLB
Professor
AJ Husband,
Executive Director
– PhD, DSc, FASM
Professor
PJ Nestel AO,
Non-Executive
Director – MD, FTSE, FRACP, FAHA
, FCSANZ
Mr PB
Simpson,
Non-Executive
Director – M
P
harm, PhC
Mr GM
Leppinus,
Non-Executive
Director – BEc, FCA
Review
of operations
Cash
Resources
At the
end of December 2008, the Consolidated Group had $44.0 million in cash resources
available to fund the drug development program and for ongoing business
requirements.
On 29
July, 2008 the Company entered into a Share Subscription Agreement with El
Coronado Holdings LLC for the placement of 4,531,633 ordinary shares at a
purchase price of $1.2215 per share raising gross proceeds of approximately $5.5
million. Following the placement El Coronado Holdings LLC holds 19.9% of the
Company’s issued and outstanding shares.
On 28
July, 2008 Marshall Edwards, Inc, (“MEI”) entered into a securities subscription
agreement with OppenheimerFunds Inc and Novogen Limited pursuant to which MEI
sold 1,700,000 and 2,908,295 shares of common stock to Oppenheimer and Novogen
respectively, at a purchase price of US$2.17 per share. The aggregate proceeds
to MEI from the sale of shares was US$10.0 million. The shares are registered
under the Securities Act of 1933, as amended, pursuant to an effective shelf
registration statement. On 30 July, 2008 MEI filed a Prospectus
Supplement to the registration Statement covering the sale of shares to
Oppenheimer and Novogen.
The
effect of these two share issues resulted in proceeds of approximately $9.0
million to the consolidated group.
The Group
has traditionally raised capital to fund its operations through the sale of
equity securities to investors. Recently the financial services industry and
credit markets have experienced a period of unprecedented turmoil. Although the
ultimate outcome of these events cannot be predicted, we may not be able to
raise the additional capital necessary, through the sale of equity securities,
to finance our Group business operations and clinical trials including the
OVATURE trial. The Group will continue its initiative to identify third party
collaboration and /or licensing opportunities and will implement cost saving
initiatives including a review of product development priorities in order to
conserve cash resources.
In
February 2009 the Company announced that it had implemented a number of cost
reduction measures including outsourcing the scale-up manufacturing of clinical
stage compounds, putting on hold the cardiovascular and anti-inflammatory
programs, reducing worldwide staff numbers from 62 to 51 and implementing fee
and income reductions of 20 per cent for the board and executive management. The
company retains its valuable patent portfolio which has derived from its
isoflavanoid technology. As the Oncology programs proceed closer to
commercialisation and when financial market conditions become more favourable
the Company will be in a better position to continue the development of the
cardiovascular and anti-inflammatory programs.
Novogen
Limited
Directors’
Report
31
December, 2008
Net
Loss
The net
loss attributable to members, after allocating outside equity interests,
decreased by $0.6 million or 6% to $9.0 million in the six months ended 31
December, 2008 from a loss of $9.6 million in the previous corresponding
period.
The net
loss for the period after income tax for the consolidated group for the six
months to 31 December, 2008 decreased by $1.1 million to $10.6 million from
$11.7 million for the same period last year. The decrease in our net loss for
the six months ended 31 December, 2008 was due to a reduction in R&D
expenses in MEI relating to the manufacturing scale-up of phenoxodiol which is
nearing completion and reduced expenditure relating to triphendiol following a
decision to put on hold its development beyond an IND pending additional funds.
These reduced expenses were partially offset by increased selling and
promotional expense relating to new product launches including the weight loss
product Aliten. Administrative expenses increased by $0.3 million (excluding net
currency gains/losses).
Revenue
The
Company earned revenue for the six months ended 31 December, 2008 of $6.4
million, a decrease of $0.4 million from $6.8 million for the same period last
year.
Sales of
consumer products decreased by $0.1 million to $4.4 million for the six months
ended 31 December, 2008 from $4.5 million for the six months ended 31 December,
2007. The decrease was primarily due to the reduction in sales revenue of $0.1
million associated with the U.K. consumer business and the reduced sales in the
Netherlands. These reductions were partially offset by increased sales in Canada
and Australia.
Sales
revenue in Australasia for the six months ended 31 December, 2008 increased $0.2
million to $2.6 million from $2.4 million for the same period last year due to
Aliten sales following product launch and the impact of additional export sales.
Sales revenue in Canada was $1.0 million for the six months ending 31 December,
2008 up from $0.9 million for the six month period last year. Sales revenue in
Europe decreased by $0.4 million to $0.8 million for the six months ending 31
December, 2008 compared to $1.2 million for the same period last year due to a
decline in the supplements market in the UK.
Revenue
from other sources for the six months ended 31 December, 2008 reduced by $0.5
million to $1.9 million from $2.4 million for the six months ended 31 December,
2007. Other revenues were affected by lower interest receipts on cash balances
following the recent reduction in interest rates
Other
Income
Other
income decreased by $1.6 million to nil for the six months ended 31 December,
2008 from $1.6 million for the six months ended 31 December 2007. During the six
months ended 31 December 2007, other Income consisted of a net gain on disposal
of the Wyong production facility which took place in October 2007.
Clinical
Trial Developments
Due to
the turmoil in the financial markets, the company may not be able to raise the
additional capital necessary to finance Group business operations and clinical
trials including the OVATURE trial.
Novogen
Limited
Directors’
Report
31
December, 2008
Anti-Cancer
Phenoxodiol
Phenoxodiol
is being developed by the Company’s subsidiary MEI as a chemosensitising agent
in combination with platinum drugs for late stage, chemoresistant ovarian cancer
and as a monotherapy for prostate and cervical cancers. Phenoxodiol is an
investigational novel-acting drug that inhibits key pro-survival signalling
pathways operating within cancer cells causing selective cancer cell death and
increased susceptibility to drugs like platinum and taxane, to which most
ovarian cancer patients become resistant in late stage disease.
OVATURE
Phase III Clinical Trial
The
OVATURE trial is a major multi-centre international Phase III clinical trial of
orally-administered phenoxodiol in combination with carboplatin in women with
advanced ovarian cancer resistant or refractory to platinum-based drugs to
determine its safety and effectiveness when used in combination with
carboplatin. The OVATURE trial has been approved by the US Food and Drug
Administration (“FDA”) under a Special Protocol Assessment (“SPA”) program
indicating that the study design, clinical endpoints and statistical analysis
are acceptable to the FDA. The protocol provides for an interim analysis of the
data, which, if statistically significant can be used to support a request for
accelerated marketing approval. An analysis of the interim results will be
possible after the targeted patient recruitment is completed and 95 patients
have withdrawn from the study due to disease progression or have
died.
The
OVATURE trial is recruiting ovarian cancer patients whose cancer initially
responded to chemotherapy but has since become resistant or refractory to
traditional platinum treatment. Patients are being recruited at clinical sites
across the US, UK, Europe and Australia.
In May
2008, the FDA granted a further patient recruitment extension because of the
slower than expected recruitment rate.
In
November 2008, a review by the Independent Data Monitoring Committee (IDMC)
recommended that the OVATURE trial continue. The IDMC is responsible to ensure
that patients recruited to the study are not exposed to unnecessary safety
risks, that the study continues to meet its clinical objectives, and that it is
run according to the required standards of Good Clinical Practice. Following a
scheduled review of safety and efficacy data, the Committee recommended that the
study remain open and continue as planned towards its target of 340
patients.
Triphendiol
Triphendiol
(NV-196) is an investigational drug in the Marshall Edwards, Inc., oncology drug
pipeline, currently being developed as an orally-delivered chemosensitising
agent, intended for use in conjunction with standard chemotoxic anti-cancer
drugs for the treatment of late stage pancreatic cancer, cholangiocarcinoma, and
melanoma. Triphendiol was granted orphan drug status by the US Food and
Drug Administration for pancreatic cancer and cholangiocarcinoma in January,
2008 and for treatment of stage IIb-IV malignant melanoma in February,
2008.
In
January 2009, MEI announced that it had been granted an Investigative New Drug
(IND) approval by he United States Food and Drug Administration (FDA) to
undertake clinical studies with triphendiol in pancreatic and bile duct cancer
as a chemosensitising agent in combination with gemcitabine.
Novogen
Limited
Directors’
Report
31
December, 2008
NV-128
NV-128 is
the latest promising oncology compound to be selected for development from the
Company’s compound portfolio.
In
contrast to phenoxodiol and triphendiol, NV-128 has been shown to induce
caspase-independent DNA degradation and cancer cell death. It appears that
in conjunction with autophagy induction, NV-128 induces caspase independent
cell death via the AKT-mTOR pathway resulting in beclin sequestration of Bcl-2,
Bax up-regulation and mitochondrial depolarisation. As a consequence,
endonuclease G translocates to the nucleus where it initiates DNA degradation
and cell death. This offers an opportunity for use as a monotherapy in
chemoresistant cancers and enhanced efficacy against cancer targets less
susceptible to phenoxodiol. The option for co-administration of
combinations of these drugs is also under investigation to extend the potential
therapeutic range of this unique class of oncology compounds.
In
October 2008, the company announced that work performed in collaboration with a
Yale University research team led by Associate Professor Gil Mor, MD, PhD, has
revealed its novel mTOR inhibitor NV-128 has the potential to act against cancer
stem cells in addition to rapidly proliferating cells in established solid
tumours.
Published
research indicates that mTOR pathways, in addition to their involvement in
maintaining survival among rapidly dividing cells in established tumours, also
guarantee survival in cancer stem cells. Cancer stem cells are slowly dividing
undifferentiated cells with capacity to regenerate tumours rapidly after
surgical or chemical removal of the tumour. These cells are now becoming
recognised as the underlying mechanism by which tumours recur and metastasise
after primary treatment. As such they represent a promising target by which
improved cancer control may be achieved.
NV-128
has been shown to function as a potent inhibitor of the mTOR pathway and
therefore has the potential to be effective against cancer stem
cells. Novogen is now aligning its research priorities for NV-128, and
other related pipeline compounds, to look specifically at their activity in
cancer stem cells. This presents a unique opportunity to develop NV-128,
and other potential derivatives, not only for use as a therapeutic agent in
established cancers, but also to target the stem cells which lead to cancer
recurrence.
Wound
Healing
GLYC-101
The
Company announced in October 2008 that its subsidiary company Glycotex, Inc had
enrolled its first patient into its Phase IIb human clinical trial
in the US which is designed to
investigate the safety and clinical outcomes of topically applied GLYC-101
compared to placebo in subjects undergoing carbon dioxide laser skin
resurfacing.
GLYC-101
is intended to stimulate and modulate the natural cascade of wound healing
activities in several cell populations. The product candidate is a topical gel
formulation to be applied directly on the wound surface. The strategic
priorities for GLYC-101 include wound healing following laser ablation, burn
wounds, surgical wounds, venous ulcers and diabetic ulcers.
Dividends
Paid or Recommended
The
Directors of Novogen Limited do not recommend the payment of a dividend. No
dividends were declared or paid during the six months ended 31 December,
2008.
Novogen
Limited
Directors’
Report
31
December, 2008
Auditor's
Independence Declaration
A copy of
the Auditor's independence declaration as required under section 307C of the
Corporations Act 2001 is included following the Directors' Report.
Rounding
The
amounts and figures shown in this report have been rounded to the nearest
thousand dollars (where rounding is applicable) under the option available to
the Company under ASIC Class Order 98/0100. The Company is an entity to which
the Class Order applies.
Signed in
accordance with a resolution of the directors on behalf of the
board.
/s/ C
Naughton
C
Naughton
Managing
Director
Sydney,
26 February, 2009
Novogen
Limited
Auditor’s
Independence Declaration
31
December, 2008
DECLARATION
OF INDEPENDENCE BY SIMON COULTON
TO
THE DIRECTORS OF NOVOGEN LIMITED
As lead
auditor for the review of Novogen Limited for the half-year ended 31 December
2008, I declare that to the best of my knowledge and belief, there have
been:
·
|
no
contraventions of the auditor independence requirements of the
Corporations Act 2001
in relation to the review;
and
|
·
|
no
contraventions of any applicable code of professional conduct in relation
to the review.
|
This
declaration is in respect of Novogen Limited and the entities it controlled
during the period.
/s/ Simon
Coulton
Simon
Coulton
Director
/s/ BDO
Kendalls
BDO
Kendalls Audit & Assurance (NSW-VIC) Pty Ltd
Sydney,
February 26, 2009
Novogen
Limited
Condensed
Income Statement
For
the half-year ended 31 December, 2008
|
|
Notes
|
|
|
Consolidated
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
$'000
|
|
|
$'000
|
|
Revenue
|
|
|
2
|
|
|
|
6,375
|
|
|
|
6,829
|
|
Other
Income
|
|
|
2
|
|
|
|
-
|
|
|
|
1,626
|
|
Expenses
|
|
|
2
|
|
|
|
(17,019
|
)
|
|
|
(20,179
|
)
|
Finance
costs
|
|
|
|
|
|
|
-
|
|
|
|
(11
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
before income tax
|
|
|
|
|
|
|
(10,644
|
)
|
|
|
(11,735
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
tax expense
|
|
|
|
|
|
|
(1
|
)
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
after tax from continuing operations
|
|
|
|
|
|
|
(10,645
|
)
|
|
|
(11,738
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
for the period
|
|
|
|
|
|
|
(10,645
|
)
|
|
|
(11,738
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
attributable to minority interest
|
|
|
|
|
|
|
1,685
|
|
|
|
2,124
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
attributable to members of Novogen Limted
|
|
|
|
|
|
|
(8,960
|
)
|
|
|
(9,614
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
and diluted earnings/(loss) per share (cents)
|
|
|
|
|
|
|
(8.8
|
)
|
|
|
(9.9
|
)
|
The
above condensed income statement should be read in conjunction with the
accompanying notes.
Novogen
Limited
Condensed
Balance Sheet
31
December, 2008
|
|
Consolidated
|
|
|
|
December
|
|
|
June
|
|
|
|
2008
|
|
|
2008
|
|
|
|
$'000
|
|
|
$'000
|
|
CURRENT
ASSETS
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
|
44,043
|
|
|
|
35,386
|
|
Trade
and other receivables
|
|
|
5,456
|
|
|
|
4,969
|
|
Inventories
|
|
|
2,485
|
|
|
|
1,929
|
|
Other
current assets
|
|
|
396
|
|
|
|
542
|
|
Total
Current Assets
|
|
|
52,380
|
|
|
|
42,826
|
|
|
|
|
|
|
|
|
|
|
NON-CURRENT
ASSETS
|
|
|
|
|
|
|
|
|
Property,
plant and equipment
|
|
|
477
|
|
|
|
575
|
|
Total
Non-Current Assets
|
|
|
477
|
|
|
|
575
|
|
|
|
|
|
|
|
|
|
|
TOTAL
ASSETS
|
|
|
52,857
|
|
|
|
43,401
|
|
|
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES
|
|
|
|
|
|
|
|
|
Trade
and other payables
|
|
|
7,222
|
|
|
|
6,671
|
|
Provisions
|
|
|
792
|
|
|
|
708
|
|
Total
Current Liabilities
|
|
|
8,014
|
|
|
|
7,379
|
|
|
|
|
|
|
|
|
|
|
NON-CURRENT
LIABILITIES
|
|
|
|
|
|
|
|
|
Provisions
|
|
|
387
|
|
|
|
385
|
|
Total
Non-Current Liabilities
|
|
|
387
|
|
|
|
385
|
|
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES
|
|
|
8,401
|
|
|
|
7,764
|
|
NET
ASSETS
|
|
|
44,456
|
|
|
|
35,637
|
|
|
|
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contributed
equity
|
|
|
205,985
|
|
|
|
200,432
|
|
Reserves
|
|
|
(225
|
)
|
|
|
(7,491
|
)
|
Accumulated
losses
|
|
|
(170,480
|
)
|
|
|
(162,251
|
)
|
Parent
interest
|
|
|
35,280
|
|
|
|
30,690
|
|
|
|
|
|
|
|
|
|
|
Minority
interest
|
|
|
9,176
|
|
|
|
4,947
|
|
|
|
|
|
|
|
|
|
|
TOTAL
EQUITY
|
|
|
44,456
|
|
|
|
35,637
|
|
The
above condensed balance sheet should be read in conjunction with the
accompanying notes.
Novogen
Limited
Condensed
Statement of Changes in Equity
For
the half-year ended 31 December, 2008
Consolidated
|
|
Contributed
Equity
|
|
|
Accumulated
losses
|
|
|
Reserves
|
|
|
Total
|
|
|
Minority
interest
|
|
|
Total
equity
|
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At
1 July 2007
|
|
|
191,876
|
|
|
|
(146,147
|
)
|
|
|
(5,155
|
)
|
|
|
40,574
|
|
|
|
4,052
|
|
|
|
44,626
|
|
Exchange
differences on translation of foreign operations
|
|
|
|
|
|
|
|
(1,344
|
)
|
|
|
(1,344
|
)
|
|
|
(517
|
)
|
|
|
(1,861
|
)
|
Share-based
payments
|
|
|
|
|
|
|
456
|
|
|
|
|
|
|
|
456
|
|
|
|
285
|
|
|
|
741
|
|
Net
income recognised directly in equity
|
|
|
-
|
|
|
|
456
|
|
|
|
(1,344
|
)
|
|
|
(888
|
)
|
|
|
(232
|
)
|
|
|
(1,120
|
)
|
Issue
of share capital by subsidiary
|
|
|
17,834
|
|
|
|
|
|
|
|
|
|
|
|
17,834
|
|
|
|
|
|
|
|
17,834
|
|
less
minority interest
|
|
|
(5,013
|
)
|
|
|
|
|
|
|
|
|
|
|
(5,013
|
)
|
|
|
5,013
|
|
|
|
-
|
|
Loss
for the period
|
|
|
|
|
|
|
(9,614
|
)
|
|
|
|
|
|
|
(9,614
|
)
|
|
|
(2,124
|
)
|
|
|
(11,738
|
)
|
Share
of opening equity transferred to minority interest due to issuance of
shares by subsidiary
|
|
|
(4,554
|
)
|
|
|
3,291
|
|
|
|
392
|
|
|
|
(871
|
)
|
|
|
871
|
|
|
|
-
|
|
At
31 December 2007
|
|
|
200,143
|
|
|
|
(152,014
|
)
|
|
|
(6,107
|
)
|
|
|
42,022
|
|
|
|
7,580
|
|
|
|
49,602
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At
1 July 2008
|
|
|
200,432
|
|
|
|
(162,251
|
)
|
|
|
(7,491
|
)
|
|
|
30,690
|
|
|
|
4,947
|
|
|
|
35,637
|
|
Exchange
differences on translation of foreign operations
|
|
|
|
|
|
|
|
7,211
|
|
|
|
7,211
|
|
|
|
2,886
|
|
|
|
10,097
|
|
Share-based
payments
|
|
|
|
|
|
|
363
|
|
|
|
|
|
|
|
363
|
|
|
|
39
|
|
|
|
402
|
|
Net
income recognised directly in equity
|
|
|
-
|
|
|
|
363
|
|
|
|
7,211
|
|
|
|
7,574
|
|
|
|
2,925
|
|
|
|
10,499
|
|
Issue
of share capital (4,531,633 shares)
|
|
|
5,527
|
|
|
|
|
|
|
|
|
|
|
|
5,527
|
|
|
|
|
|
|
|
5,527
|
|
Issue
of share capital by subsidiary
|
|
|
3,438
|
|
|
|
|
|
|
|
|
|
|
|
3,438
|
|
|
|
|
|
|
|
3,438
|
|
less
minority interest
|
|
|
(2,909
|
)
|
|
|
|
|
|
|
|
|
|
|
(2,909
|
)
|
|
|
2,909
|
|
|
|
-
|
|
Loss
for the period
|
|
|
|
|
|
|
(8,960
|
)
|
|
|
|
|
|
|
(8,960
|
)
|
|
|
(1,685
|
)
|
|
|
(10,645
|
)
|
Share
of opening equity transferred to minority interest due to issuance of
shares by subsidiary
|
|
|
(503
|
)
|
|
|
368
|
|
|
|
55
|
|
|
|
(80
|
)
|
|
|
80
|
|
|
|
-
|
|
At
31 December 2008
|
|
|
205,985
|
|
|
|
(170,480
|
)
|
|
|
(225
|
)
|
|
|
35,280
|
|
|
|
9,176
|
|
|
|
44,456
|
|
The
above condensed statement of changes in equity should be read in conjunction
with the accompanying notes.
Novogen
Limited
Condensed
Cash Flow Statement
For
the half-year ended 31 December, 2008
|
|
Consolidated
|
|
|
|
2008
|
|
|
2007
|
|
|
|
$'000
|
|
|
$'000
|
|
|
|
|
|
|
|
|
Cash
flows from operating activities
|
|
|
|
|
|
|
Net
(loss) before tax
|
|
|
(10,644
|
)
|
|
|
(11,735
|
)
|
Income
tax paid
|
|
|
(1
|
)
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
Adjustments
to reconcile net (loss) to net cash used in operating
activities:
|
|
|
|
|
|
Depreciation
and amortisation
|
|
|
149
|
|
|
|
188
|
|
Net
(gain)/loss on disposal of property, plant and equipment
|
|
|
2
|
|
|
|
(1,626
|
)
|
Share-based
payments
|
|
|
402
|
|
|
|
208
|
|
Net
(gain)/loss on exchange rate changes
|
|
|
(923
|
)
|
|
|
124
|
|
|
|
|
|
|
|
|
|
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
(increase)/decrease
in trade receivables
|
|
|
284
|
|
|
|
806
|
|
(increase)/decrease
in other receivables
|
|
|
(771
|
)
|
|
|
700
|
|
(increase)/decrease
in inventories
|
|
|
(556
|
)
|
|
|
1,234
|
|
(increase)/decrease
in prepayments
|
|
|
146
|
|
|
|
160
|
|
increase/(decrease)
in trade and other payables
|
|
|
551
|
|
|
|
878
|
|
increase/(decrease)
in provisions
|
|
|
86
|
|
|
|
61
|
|
|
|
|
|
|
|
|
|
|
Net
cash flows used in operating activities
|
|
|
(11,275
|
)
|
|
|
(9,005
|
)
|
|
|
|
|
|
|
|
|
|
Cash
flows from investing activities
|
|
|
|
|
|
|
|
|
Acquisition
of property, plant and equipment
|
|
|
(57
|
)
|
|
|
(59
|
)
|
Proceeds
from sale of plant and equipment
|
|
|
1
|
|
|
|
3,831
|
|
|
|
|
|
|
|
|
|
|
Net
cash flows from/(used in) investing activities
|
|
|
(56
|
)
|
|
|
3,772
|
|
|
|
|
|
|
|
|
|
|
Financing
Activities
|
|
|
|
|
|
|
|
|
Proceeds
from the issue of ordinary shares
|
|
|
5,527
|
|
|
|
-
|
|
Proceeds
from the issue of shares by subsidiary
|
|
|
3,438
|
|
|
|
18,366
|
|
|
|
|
|
|
|
|
|
|
Net
cash provided by/(used in) financing activities
|
|
|
8,965
|
|
|
|
18,366
|
|
|
|
|
|
|
|
|
|
|
Net
increase/(decrease) in cash and cash equivalents
|
|
|
(2,366
|
)
|
|
|
13,133
|
|
Cash
and cash equivalents at beginning of period
|
|
|
34,386
|
|
|
|
38,511
|
|
Effect
of exchange rates on cash holdings in foreign currencies
|
|
|
11,023
|
|
|
|
(1,984
|
)
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents at end of period *
|
|
|
43,043
|
|
|
|
49,660
|
|
*
Note: an additional $1,000,000 is held as secured cash and is not included
in cash and cash equivalents in this cash flow statement.
|
|
The
above condensed cash flow statement should be read in conjunction with the
accompanying notes.
Novogen
Limited
Notes
to the Half-Year Financial Statements
31
December, 2008
Note
1. Basis of preparation of the half-year financial report
The
half-year consolidated financial statements are a general purpose financial
report prepared in accordance with the requirements of the Corporations Act
2001, Australian Accounting Standard AASB 134: Interim Financial Reporting, and
other authoritative pronouncements of the Australian Accounting Standards Board.
The financial report has also been prepared on a historical cost basis with all
amounts presented in Australian dollars, unless otherwise stated.
It is
recommended that this financial report be read in conjunction with the annual
financial report for the year ended 30 June, 2008 and any public announcements
made by Novogen Limited and its controlled entities during the half-year in
accordance with the continuous disclosure requirements arising under the
Corporations Act 2001. The half-year financial report does not include full
disclosures of the type normally included within the annual financial
report.
Statement
of compliance
The
financial report complies with Australian Accounting Standards, being Australian
equivalents to International Financial Reporting Standards (AIFRS). Compliance
with AIFRS ensures that the financial report, comprising the financial
statements and notes thereto, complies with International Financial Reporting
Standards (IFRS).
Reporting
Basis and Conventions
The
accounting policies and methods of computation followed in this interim
financial report are consistent with those applied in the annual report for the
year ended 30 June, 2008.
Novogen
Limited
Notes
to the Half-Year Financial Statements
31
December, 2008
Note
2. Revenue and expenses
|
|
Consolidated
|
|
|
|
2008
|
|
|
2007
|
|
|
|
$'000
|
|
|
$'000
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
from the sale of goods
|
|
|
4,436
|
|
|
|
4,450
|
|
|
|
|
|
|
|
|
|
|
Bank
Interest
|
|
|
616
|
|
|
|
1,032
|
|
Royalties
|
|
|
1,323
|
|
|
|
1,164
|
|
Licence
fees
|
|
|
-
|
|
|
|
28
|
|
Other
revenue
|
|
|
-
|
|
|
|
155
|
|
|
|
|
1,939
|
|
|
|
2,379
|
|
|
|
|
|
|
|
|
|
|
Total
revenue
|
|
|
6,375
|
|
|
|
6,829
|
|
|
|
|
|
|
|
|
|
|
Other
Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
gain on disposal of assets held for sale
|
|
|
-
|
|
|
|
1,626
|
|
|
|
|
-
|
|
|
|
1,626
|
|
Novogen
Limited
Notes
to the Half-Year Financial Statements
31
December, 2008
|
|
Consolidated
|
|
|
|
2008
|
|
|
2007
|
|
|
|
$'000
|
|
|
$'000
|
|
Expenses
|
|
|
|
|
|
|
Cost
of goods sold
|
|
|
(1,337
|
)
|
|
|
(2,050
|
)
|
Shipping
and handling expenses
|
|
|
(156
|
)
|
|
|
(139
|
)
|
Selling
and promotion expenses
|
|
|
(3,982
|
)
|
|
|
(3,276
|
)
|
Research
& development expenses
|
|
|
(8,081
|
)
|
|
|
(9,879
|
)
|
Administration
expenses
|
|
|
|
|
|
|
|
|
Administration
- Net currency gains/(losses)
|
|
|
923
|
|
|
|
(124
|
)
|
Administration
- other expenses
|
|
|
(4,361
|
)
|
|
|
(4,081
|
)
|
Other
expenses*
|
|
|
(25
|
)
|
|
|
(630
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
(17,019
|
)
|
|
|
(20,179
|
)
|
|
|
|
|
|
|
|
|
|
Borrowing
costs
|
|
|
-
|
|
|
|
(11
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses
included in the numbers above, specifically disclosed:
|
|
Depreciation
of non-current assets
|
|
|
|
|
|
|
|
|
Plant
and equipment
|
|
|
(138
|
)
|
|
|
(177
|
)
|
Leasehold
improvements
|
|
|
(11
|
)
|
|
|
(11
|
)
|
|
|
|
|
|
|
|
|
|
Total
depreciation and amortisation expenses
|
|
|
(149
|
)
|
|
|
(188
|
)
|
|
|
|
|
|
|
|
|
|
Expense
of share-based payments
|
|
|
(402
|
)
|
|
|
(208
|
)
|
|
|
|
|
|
|
|
|
|
*2007
includes expenses related to reassessment of expected grant income of
$915,000 and reversal of inventory impairment provision of
$285,000.
|
|
Novogen
Limited
Notes
to the Half-Year Financial Statements
31
December, 2008
Note
3. Contingent assets and liabilities
Since the
last annual reporting date, there has been no other material changes in any
contingent assets or contingent liabilities.
Note
4. Segment information
Segment
Accounting Policies
The Group
generally accounts for inter-company sales and transfers as if the sales or
transfers were to third parties at current market prices. Revenues are
attributed to geographic areas based on the location of the assets producing the
revenues.
Primary
Segment
Geographical
Segments
|
|
Australia/NZ
|
|
|
North
America
|
|
|
Europe
|
|
|
Elimination
|
|
|
Consolidated
(continuing operations)
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
|
$'000
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales
to customers outside the consolidated entity
|
|
|
2,621
|
|
|
|
2,354
|
|
|
|
1,038
|
|
|
|
900
|
|
|
|
777
|
|
|
|
1,196
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,436
|
|
|
|
4,450
|
|
Other
revenues from customers outside the consolidated entity
|
|
|
1,348
|
|
|
|
1,344
|
|
|
|
-
|
|
|
|
3
|
|
|
|
14
|
|
|
|
-
|
|
|
|
(39
|
)
|
|
|
-
|
|
|
|
1,323
|
|
|
|
1,347
|
|
Intersegment
Revenues
|
|
|
782
|
|
|
|
550
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(782
|
)
|
|
|
(550
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
segment revenue
|
|
|
4,751
|
|
|
|
4,248
|
|
|
|
1,038
|
|
|
|
903
|
|
|
|
791
|
|
|
|
1,196
|
|
|
|
(821
|
)
|
|
|
(550
|
)
|
|
|
5,759
|
|
|
|
5,797
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unallocated
revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
616
|
|
|
|
1,032
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Consolidated Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,375
|
|
|
|
6,829
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Results
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment
result
|
|
|
(10,003
|
)
|
|
|
(7,502
|
)
|
|
|
(15,286
|
)
|
|
|
(1,219
|
)
|
|
|
(970
|
)
|
|
|
(487
|
)
|
|
|
15,615
|
|
|
|
(2,516
|
)
|
|
|
(10,644
|
)
|
|
|
(11,724
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unallocated
expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
(11
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
entity loss before income tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10,644
|
)
|
|
|
(11,735
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
tax expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10,645
|
)
|
|
|
(11,738
|
)
|
Novogen
Limited
Notes
to the Half-Year Financial Statements
31
December, 2008
Note
5. Net tangible assets per share
|
|
Consolidated
|
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
Net
tangible asset backing per share
|
|
$
|
0.44
|
|
|
$
|
0.51
|
|
Note
6. Events after balance sheet date
Novogen
has undertaken a review of its development programs in order to reduce costs so
that existing cash reserves are devoted to maintaining the significant potential
of the oncology program.
In
February 2009, Novogen announced that it had reduced world wide staff numbers
from 62 to 51. The one-off costs associated with this restructure including
severance, redundancy and outplacement amounted to $423,000.
There
have been no other significant events occurring after balance date which have
had a material impact on the business.
Novogen
Limited
Directors’
Declaration
31
December, 2008
Financial
report for the half-year ended 31 December, 2008
The
Directors declare that the financial statements and notes as set out on pages 9
to 17 are in accordance with the Corporations Act 2001; and
(a)
comply with Accounting Standard AASB 134 Interim Financial Reporting and the
Corporations Regulations 2001; and
(b) give
a true and fair view of the consolidated entity's financial position as at 31
December, 2008 and of its performance, as represented by the results of its
operations and cash flows, for the half-year ended on that date.
In the
Directors' opinion:
(a) the
financial statements and notes are in accordance with the Corporations Act 2001;
and
(b) there
are reasonable grounds to believe that the Company will be able to pay its debts
as and when they become due and payable.
This
declaration is made in accordance with a resolution of Directors.
On behalf
of the board
/s/ C
Naughton
C
Naughton
Managing
Director
Sydney,
26 February, 2009
Novogen
Limited
Independent
Review Report
31
December, 2008
INDEPENDENT
AUDITOR’S REVIEW REPORT TO THE
MEMBERS
OF NOVOGEN LIMITED
Report
on the Half-Year Financial Report
We have
reviewed the accompanying half-year financial report of
Novogen Limited, which comprises the condensed balance sheet as at 31
December 2008, and the condensed income statement, condensed statement of
changes in equity and condensed cash flow statement for the half-year ended on
that date, a statement of accounting policies, other selected explanatory notes
and the directors’ declaration
of
the consolidated entity comprising the disclosing entity and the entities it
controlled at the half-year end or from time to time during the half-year in
order for the disclosing entity to lodge the half-year financial report with the
Australian Securities and Investments Commission.
Directors’
Responsibility for the Half-Year Financial Report
The
directors of the disclosing entity are responsible for the preparation and fair
presentation of the half-year financial report in accordance with Australian
Accounting Standards (including the Australian Accounting Interpretations) and
the
Corporations Act
2001
. This responsibility includes establishing and maintaining internal
control relevant to the preparation and fair presentation of the half-year
financial report that is free from material misstatement, whether due to fraud
or error; selecting and applying appropriate accounting policies; and making
accounting estimates that are reasonable in the circumstances.
Novogen
Limited
Independent
Review Report
31
December, 2008
Auditor’s
Responsibility
Our
responsibility is to express a conclusion on the half-year financial report
based on our review. We conducted our review in accordance with Auditing
Standard on Review Engagements ASRE 2410
Review of Interim and Other
Financial Reports Performed by the Independent Auditor of the Entity
, in
order to state whether, on the basis of the procedures described, we have become
aware of any matter that makes us believe that the financial report is not in
accordance with the
Corporations Act 2001
including: giving a true and fair view of the disclosing entity’s financial
position as at 31 December 2008 and its performance for the half-year ended on
that date; and complying with Accounting Standard AASB 134
Interim Financial Reporting
and the
Corporations
Regulations 2001
. As the auditor of Novogen Limited, ASRE 2410 requires
that we comply with the ethical requirements relevant to the audit of the annual
financial report.
A review
of a half-year financial report consists of making enquiries, primarily of
persons responsible for financial and accounting matters, and applying
analytical and other review procedures. A review is substantially less in scope
than an audit conducted in accordance with Australian Auditing Standards and
consequently does not enable us to obtain assurance that we would become aware
of all significant matters that might be identified in an audit. Accordingly, we
do not express an audit opinion.
Independence
In
conducting our review, we have complied with the independence requirements of
the
Corporations Act
2001
. We confirm that the independence declaration required by the
Corporations Act 2001
would
be in the same terms if it had been given to the directors at the time that this
auditor’s review report was made.
Novogen
Limited
Independent
Review Report
31
December, 2008
Conclusion
Based on
our review, which is not an audit, we have not become aware of any matter that
makes us believe that the half-year financial report of Novogen Limited is not
in accordance with the
Corporations Act 2001
including:
|
(a) giving
a true and fair view of the consolidated entity’s financial position as at
31 December 2008 and of its performance for the half-year ended on that
date; and
|
|
(b) complying
with Accounting Standard AASB 134
Interim Financial
Reporting
and Corporations Regulations
2001.
|
/s/ BDO
Kendalls Audit & Assurance (NSW-VIC) Pty Ltd
BDO
Kendalls Audit & Assurance (NSW-VIC) Pty Ltd
/s/
Simon Coulton
Simon
Coulton
Director
Sydney,
February 26, 2009
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024